Uncategorized

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial – Gilead Sciences

Posted on Author Comments Off on Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial – Gilead Sciences

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial  Gilead SciencesGilead’s twice-yearly shot cut HIV infections by 96% in trial  CNBCTwice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill  CNNAn injectable HIV-prevention drug is highly effective — but wildly expensive  NBC NewsPublic Pharma vs. abusive prices: the case of the latest HIV-prevention drug  Peoples Dispatch